Culver City-based cannabis company MedMen Enterprises Inc. announced its acquisition of PharmaCann in an all-stock deal valued at $682 million.
The pending transaction marks the largest acquisition in the cannabis industry in the U.S. and almost doubles MedMen’s retail and cultivation facilities across the country. Chicago-based PharmaCann is the largest retailer of medical marijuana in the U.S.
The combined company will have a total of 79 cannabis licenses across 12 states, which includes 66 retail stores and 13 cultivation licenses, the company said.
MedMen has licenses in Arizona, California, Florida, Illinois, Nevada, and New York and with the PharmaCann acquisition it stands to gain licenses in Massachusetts, Maryland, Michigan, Virginia, Ohio and Pennsylvania.
"This is a transformative acquisition that will create the largest U.S. cannabis company in the world's largest cannabis market," Chief Executive Adam Bierman, said in a statement. "The transaction adds tremendous scale to our vertically integrated business model by expanding our U.S. retail footprint across important growth markets.”
Founded in 2010, MedMen went public through a reverse merger with Ladera Ventures Corp. in May. The company raised $110 million through a private placement and opted to go public on the Canadian Securities Exchange as marijuana is still illegal under U.S. federal law.
Manufacturing, retail and trade reporter Shwanika Narayan can be reached at firstname.lastname@example.org or 323-556-8351. Follow her on Twitter @shwanika.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- MedMen Terminates PharmaCann Purchase, CFO
- MedMen Enterprises Strikes Deal to Acquire PharmaCann, Form New Firm
- MedMen Posts $67M Loss for 2018 Despite Soaring Pot Sales
- MedMen Enterprises Names Interim CFO
- MedMen to Pay $53 Million for Florida Pot Nursery and Dispensary Rights
- MedMen Gets $30 Million Bump to Credit Line, Plans More Store Openings
- MedMen CFO Slashes Costs
- Cannabis Firm MedMen Nears Public Offering; Valuation North of $1.6 Billion